Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a ...

Sionna Therapeutics SION) stock rises as the clinical-stage biopharma focused on cystic fibrosis therapies makes its public ...

A new study has demonstrated that a combination of conditional cash transfers and TB counseling significantly improves treatment success rates and reduces loss to follow-up among TB patients in South ...

Insmed Incorporated INSM announced that the FDA has accepted its new drug application (“NDA”) seeking approval of its reversible inhibitor of dipeptidyl peptidase 1 (DPP1), brensocatib, for treating ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...

Sionna Therapeutics, Inc SION IPO will take place February, 07 on the NASDAQ exchange under the ticker SION. The company is ...

Cystic fibrosis is a genetic disorder that changes a vital protein in the body, causing a buildup of thick and sticky mucus, ...

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...